Appropriate cellular levels of polyamines are required for cell growth and differentiation. Ornithine decarboxylase is a key regulatory enzyme in the biosynthesis of polyamines, and precise regulation of the expression of this enzyme is required, according to cellular growth state. A variety of mitogens increase the level of ornithine decarboxylase activity, and, in most cases, this elevation is due to increased levels of mRNA. A GC box in the proximal promoter of the ornithine decarboxylase gene is required for basal and induced transcriptional activity, and two proteins, Sp1 and NF-ODC 1 , bind to this region in a mutually exclusive manner. Polyamines are essential cations for normal cell growth and differentiation (1, 2). Increased synthesis of these compounds is closely associated with, and necessary for, stimulated cell proliferation and tumor promotion. Tight regulation of polyamine biosynthesis is important as overproduction of these compounds can be toxic to cells (3, 4). Ornithine decarboxylase (ODC) 1 catalyzes a key regulated step in polyamine synthesis, and regulation of ODC activity is a major mechanism for controlling polyamine concentrations within cells. The activity of this enzyme is tightly regulated during normal cell growth and differentiation. An increase in ODC activity is required for reentry of quiescent cells into the cell cycle (2, 5-7). Deregulated expression of ODC and the subsequent changes in polyamine concentrations have been associated with several types of tumors (4, 8 -10). Recent studies indicate that overexpression of oncogenes such as myc (11-13), ras (14), fos (15), and mos (16) result in elevated levels of ODC expression. Importantly, two studies have shown that overexpression of ODC in fibroblasts induces neoplastic transformation and suggest a direct link between deregulation of ODC expression and oncogenesis (17, 18) .
Polyamines are essential cations for normal cell growth and differentiation (1, 2) . Increased synthesis of these compounds is closely associated with, and necessary for, stimulated cell proliferation and tumor promotion. Tight regulation of polyamine biosynthesis is important as overproduction of these compounds can be toxic to cells (3, 4) . Ornithine decarboxylase (ODC) 1 catalyzes a key regulated step in polyamine synthesis, and regulation of ODC activity is a major mechanism for controlling polyamine concentrations within cells. The activity of this enzyme is tightly regulated during normal cell growth and differentiation. An increase in ODC activity is required for reentry of quiescent cells into the cell cycle (2, (5) (6) (7) . Deregulated expression of ODC and the subsequent changes in polyamine concentrations have been associated with several types of tumors (4, 8 -10) . Recent studies indicate that overexpression of oncogenes such as myc (11) (12) (13) , ras (14) , fos (15) , and mos (16) result in elevated levels of ODC expression. Importantly, two studies have shown that overexpression of ODC in fibroblasts induces neoplastic transformation and suggest a direct link between deregulation of ODC expression and oncogenesis (17, 18) .
Both activation and inhibition of ODC activity is required for precise regulation of ODC levels. A broad spectrum of stimuli, including hormones, growth factors, tumor promoters and oncogenes elevates ODC activity in the cell. In most cases, these increases in activity result from enhanced levels of ODC mRNA (6, 7) . Several of the DNA elements and protein factors involved in both basal and stimulated activity of the ODC promoter have been identified, including several binding sites for transcription factor Sp1, two binding sites for members of the CREB/ ATF family of transcription factors, and binding sites for transcription factors related to c-myc (7) . Little is known about DNA elements or protein factors that are involved in repressing ODC transcription. A GC-rich region located at Ϫ123 to Ϫ91 relative to the transcriptional start site of the ODC promoter seems to be such an element. We have demonstrated that two proteins bind this site in a mutually exclusive manner, Sp1 and NF-ODC 1 (19) . Sp1 is a well characterized transcription factor that is found in most eukaryotic cell and is directly involved in both basal and induced expression of many genes. NF-ODC 1 has been characterized only through in vitro binding assays. Point mutations that eliminate NF-ODC 1 binding, but maintain Sp1 binding, elevate basal activity relative to the wild type promoter (19) . These results suggest that NF-ODC 1 functions to repress the transcriptional activity of the ODC gene.
The goal of the present study was to identify the protein responsible for NF-ODC 1 binding activity. We have used a yeast one-hybrid system to isolate cDNAs that code for NF-ODC 1 . One of the isolated cDNAs encoded the human homologue of ZBP-89, a known DNA-binding protein that acts to repress both basal and induced expression of the gastrin gene (20) . Several lines of evidence, including copurification, demonstrate that ZBP-89 is the protein responsible for the NF-ODC 1 binding activity. ZBP-89 represses Sp1 activation of the ODC promoter in Schneider's Drosophila line 2 (SL2) cells, consistent with properties previously attributed to NF-ODC 1 .
MATERIALS AND METHODS

Cell Culture and Preparation of Nuclear Extracts-
The human Jurkat T-cell line was cultured in RPMI 1640 (Life Technologies, Inc.) supplemented with 10% calf serum, 10 mM Hepes, pH 7.5, and 2 mM L-glutamine on 150-mm culture dishes. Jurkat cells were grown in 6-liter spinner flasks from which nuclear extracts were prepared for * This work was supported in part by United States Public Health Service Grants DE08229 (to D. R. M.) and DK45729 (to J. L. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBank TM /EBI Data Bank with accession number(s) AF039019. ** To whom correspondence should be addressed: Dept. of Biochemistry, Box 357350, University of Washington, Seattle, WA 98195-7350. Fax: 206-543-4822; E-mail: dmorris@u.washington.edu. 1 The abbreviations used are: ODC, ornithine decarboxylase; EMSA, electrophoretic mobility shift assay; SL2, Schneider's Drosophila line 2; TBE, Tris-borate/EDTA electrophoresis buffer; GCF, GC factor; MAZ, MYC-associated zinc finger protein; TCR, T-cell receptor.
NF-ODC 1 purification. HeLa cells were cultured in Dulbecco's modified Eagle's medium (Cellgro, Herndon, VA) and 10% calf serum. SL2 cells (ATCC, Rockville, MD) were grown at 27 o , in Shield and Sang M3 insect medium, pH 6.6 (Sigma) and 10% fetal bovine serum, heat-inactivated (Sigma; catalog no. F-3018). All media contained 100 units of penicillin and 100 g of streptomycin/ml. Nuclear extracts were prepared as outlined in Ref. 21 , based on the protocol by Dignam and co-workers (22) . Phosphatase inhibitors Na 2 MoO 4 and NaF were added to all buffers at 0.1 mM and 10 mM, respectively. The high salt buffer contained 1.2 M KCl. The following protease inhibitors were added to the buffers immediately before use, at the indicated final concentrations: phenylmethylsulfonyl fluoride (1 mM), pepstatin A (1 g/ml), leupeptin (1 g/ml), aprotinin (1 g/ml), and antipain (5 g/ml). The nuclear extract was not dialyzed, but stored in appropriate sized aliquots at Ϫ70°C until use.
Electrophoretic Mobility Shift Assay (EMSA) and Oligonucleotide Sequences-Binding reactions (final volume 20 l) contained in addition to the protein sample: 0.1 pmol of probe, 200 -300 mM KCl, 2 g of double-stranded poly(dI-dC), and 1.0 g of sheared salmon sperm DNA in gel shift buffer (20 mM Hepes, pH 7.9, 10% glycerol, 6 mM MgCl 2 , 1 mM EDTA, 100 M ZnSO 4 ). In experiments utilizing unlabeled doublestranded oligonucleotides as specific competitors, the protein was added to the reaction after the DNA. Binding reactions were incubated for 20 min at 4°C before loading on a 5% polyacrylamide gel (acrylamide: bisacrylamide ratio of 37.5:1, 0.5ϫ Tris-borate/EDTA electrophoresis buffer (TBE: 45 mM Tris base, 45 mM boric acid, and 1 mM EDTA), 5% glycerol, 3-mm-thick gel) that had been pre-run for 1 h. After running in the cold room at 200 V in 0.5ϫ TBE for 4 -6 h and drying, the gel was exposed to film with an intensifying screen for several hours to 2 days as necessary. The probes (1.0 -0.5 ϫ 10 5 cpm/l and 0.05 pmol/l) were made by end-labeling double-stranded oligonucleotides with T4 polynucleotide kinase and [␥-
32 P]ATP. NICK ® spin columns (Amersham Pharmacia Biotech) were used to remove non-incorporated isotope. When required, phosphorimage analysis was performed to quantitate signal intensities.
Slightly different conditions were used to assay for MAZ binding: 10 l of 2ϫ MAZ gel shift buffer (0.1% Nonidet P-40, 2% glycerol, 1 M ZnSO 4 , 10 mM Tris, pH 7.5, 70 mM KCl, 1 mM dithiothreitol, and 2.5 mM MgCl 2 ) were used per 20-l reaction, and double-stranded poly(dA-dT) was used instead of double-stranded poly(dI-dC) as a nonspecific competitor. The gels were run in 0.25ϫ TBE at 200 V for 8 h. The MAZ antibody was kindly provided by Kenneth B. Marcu (State University of New York, Stony Brook, NY).
In "supershift" experiments, the antibody was added to reaction mixtures containing protein, but no probe. The antibody-protein solution was incubated for 1-3 h at 4°C, followed by the addition of the probe and an additional incubation at 4°C for 20 min before loading the binding reaction onto the gel. Control peptides or antigens were incubated overnight at 4°C with antibodies prior to use in the binding reactions. The antibodies and control peptides for the Sp1 family of proteins were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Rabbit polyclonal antibodies were raised against a glutathione S-transferase fusion protein that included amino acids 1-521 of rat ZBP-89 (Rockland, Gilbertsville, PA) (23) . Anti-ZBP-89 was the IgG fraction from the rabbit antisera. Oligonucleotides were purchased from Life Technologies, Inc. Shown are the upper strand sequences for the double-stranded oligonucleotides used. GC N contained the NF-ODC 1 binding site and GC S contained the Sp1 binding site from the ODC promoter. GC WT , 5Ј-CCACGGAGTCCCCGCCCCTCCCCCGCGCCTCC- C-3Ј; GC  N , 5Ј-GGCCGATGCGCCCCTCCCCCGCGCCGATC-3Ј; GC  S ,  5Ј-GGCCGGATGCCCCGCCCCTCCCGGCC-3Ј; GC  WT6 , 5Ј-CGGAGTA-TGCACCCCTCCCCCGCGCCTC-3Ј; GCF, 5Ј-GCCAACGCCCCGCAA-CCG-3Ј; Egr-1, 5Ј-CGGCCCGCCCCCGCAACCCGAGCC-3Ј; MAZ, 5Ј-G-ATCCCTCCCCTCCCTTCTTTTTC-3Ј; E box, 5Ј-GGAAGCAGACCACG-TGGTCTGCTTCC-3Ј .
Isolation of the NF-ODC 1 cDNA-The MATCHMAKER One-Hybrid System from CLONTECH was one method used to isolate the cDNA encoding for the protein responsible for the NF-ODC 1 binding activity. The MATCHMAKER One-Hybrid System protocol was used to prepare the target-reporter constructs, to integrate these constructs into Saccharomyces cerevisiae strainYM4271, to screen the AD fusion library (Human Leukemia MATCHMAKER cDNA Library, CLONTECH), and to isolate plasmid from each candidate clone. Two pairs of oligonucleotides were synthesized (Genset, La Jolla, CA). When annealed, the double-stranded oligonucleotides consisted of either three tandem copies of the wild type NF-ODC 1 binding site or three tandem copies of a mutated NF-ODC 1 binding site. Wild type oligonucleotides: 5Ј-AATTC-AGCCCCTCCCCCGAAGCCCCTCCCCCGATAGCCCCTCCCCCGTC-TAGAGCTACGAG-3Ј and 5Ј-TCGACTCGTAGCTCTAGACGGGGGAG-GGGCTATCGGGGGAGGGGCTTCGGGGGAGGGGCTG-3Ј. Mutated oligonucleotides: 5Ј-AATTCAGCCCCTCCCAAGAAGCCCCTCCCAAG-ATAGCCCCTCCCAAGT-3Ј and 5Ј-CTAGACTTGGGAGGGGCTATCT-TGGGAGGGGCTTCTTGGGAGGGGCTG-3Ј. The wild type target site was placed upstream of both the pHis-1 and pLacZi plasmids. The mutated target site was place upstream of pHis-1. The target-reporter constructs were transformed into S. cerevisiae strain YM4271. The two wild type reporter constructs (pHis-1 and pLacZi) were transformed in a consecutive manner to produce a dual reporter strain. The plasmid DNA, isolated from the yeast candidate clones, was transformed into DH5␣ cells. Plasmid DNA was isolated from the transformed bacteria and transformed into the strain containing the mutated target reporter. The Gene Trapper™ cDNA positive selection system (Life Technologies, Inc.) with a Superscript™ cDNA human leukocyte library (Life Technologies, Inc.) was also used to isolate ZBP-89 cDNAs using the following primers from the NH 2 -terminal domain of ht␤: HTB-1, 5Ј-T-CAAGATCGAAGTATGCCTCAC-3Ј; HTB-2, 5Ј-GCTCTGAGGAAGAT-TCTGGGC-3Ј; and HTB-3A, 5Ј-TGCCTTCTGAGTCCAGTAAAG-3Ј.
In Vitro Translations-In vitro coupled transcription/translation reactions were performed using the TNT ® coupled reticulocyte lysate system (Promega, Madison, WI). The pET-human ZBP-89 expression vector was constructed by inserting the BamHI/BglII fragment from positive clones into the BamHI site of the pET-3b vector (Novagen, Madison, WI). The MAZ expression vector, MAZHH, (provided by Kenneth B. Marcu, State University of New York, Stony Brook, NY) was used for the in vitro transcription/translation of MAZ. The unmodified pBKCMV (control vector), pBKCMV containing the full-length rat ZBP-89 cDNA or pBKCMV containing the truncated rat ZBP-89 cDNA (designated B22) as described by Merchant et al. (20) were used to prepare in vitro transcription/translation products as indicated under "Results."
Enrichment of Activity and Immunoblot Analysis-Jurkat nuclear extract was precipitated by slowly adding solid ammonium sulfate to a final concentration of 53% saturation. The resulting pellet was resuspended in CB (25 mM Tris, pH 7.9, 10% glycerol, 1 mM dithiothreitol, 5 mM EDTA, 10 mM NaF, 10 mM Na 2 MoO 4 , 100 M ZnSO 4 , and 0.1% Nonidet P-40). The redissolved protein extract was applied to a P6 (Bio-Rad) desalting column (equilibrated in CB buffer) to remove remaining (NH 4 ) 2 SO 4 . The protein fraction from the P6 column was applied to a Mono Q column (Bio-Rad, Hercules, CA), pre-equilibrated in CB, and the bound proteins were eluted using a 0 -500 mM KCl gradient in CB. The NF-ODC 1 binding activity eluted at approximately 350 mM KCl. The fractions containing NF-ODC 1 were pooled, diluted to 100 mM KCl with DA buffer (25 mM Hepes, pH 7.6, 12.5 mM MgCl 2 , 1 mM dithiothreitol, 20% glycerol ,and 0.1% Nonidet P-40), and applied to a DNA affinity column (see below), and the NF-ODC 1 activity was eluted from the column with DA buffer containing 600 mM KCl. The following protease inhibitors were added to CB and DA buffers immediately before use, at the indicated final concentrations: phenylmethylsulfonyl fluoride (1 mM), pepstatin A (1 g/ml), leupeptin (1 g/ml), aprotinin (1 g/ml), and antipain (5 g/ml). The DNA affinity column matrix was made using double-stranded oligonucleotide, GC N ( Fig. 1) , in which the upper strand was biotinylated at the 5Ј end (Genset, La Jolla, CA). The biotinylated GC N was coupled to streptavidin-agarose beads (75 g of DNA/500 l of agarose bead) using the procedure and buffers outlined by Ostrowski and Bomsztyk (24) . EMSAs using GC N as probe were using during this procedure to determine the NF-ODC 1 -containing protein fractions. For immunoblot analysis, protein samples were fractionated on a 7.5% SDS-polyacrylamide gel and transferred to a polyvinylidene fluoride membrane (PolyScreen, NEN™ Life Science Products) using standard techniques and a mini-gel format. Phototope ® -HRP Western blot detection kit and protocol (New England Biolabs, Inc., Beverly, MA) were used for antigen detection. Anti-ZBP-89 (1:1000) was used as the primary antibody. Band intensities were quantitated by densitometry.
Transfection of SL2 Cells-SL2 cells were transfected using a modification of a previously described method (25) . Cells were plated at 1-2 ϫ 10 6 cells/60-mm dish, approximately 20 h before transfection. Calcium-phosphate complexes were made by the dropwise addition of the DNA/CaCl 2 solution into 2ϫ Hepes-buffered saline while bubbling the mixture. After 20 min at room temperature, the suspension of calcium-phosphate complexes was added dropwise to the culture dishes. The following plasmids were used. ␥F-gal is an internal control plasmid in which the E. coli ␤-galactosidase gene is under the control of the Drosophila melanogaster hsp70 core promoter (26) and was kindly provided by Dr. Pier Paolo Di Nocera (Università degli Studi di Napoli Fecerico II, Napoli, Italy). The pPacSp1 expression plasmid and the parental pPac plasmid, pPacO, have been described previously (27) and were kindly provided by Dr. Robert Tjian (University of California at Berkeley, Berkeley, CA). The pOD150WTLuc construct contained the ODC sequence from Ϫ133 to ϩ16 in the pGL2-basic vector (Promega, WI) with a modified multiple cloning site. Twenty base pairs (Ϫ104 to Ϫ84) were removed from pOD150WTLuc with a method for site-directed mutagenesis using the polymerase chain reaction as outlined by Hemsley et al. The sequences of the two primers used were: 5Ј-AGGG-GCGGGGACTCCGTG-3Ј and 5Ј-AACCGATCGCGGCTGGTT-3Ј. The resulting construct, pOD150M12Luc, retained the entire Sp1 binding site but only 6 out of 11 base pairs of the ZBP-89 binding site. BCAT-S was created by cutting BCAT-1 (29) with PstI and SalI to removing the HTLVIII LTR Sp1 binding site. A double-stranded oligonucleotide containing the ODC Sp1 binding site with PstI and SalI ends was inserted. The sequence of the annealed oligonucleotides were: 5Ј-GCGGATGCC-CCGCCCCGATG-3Ј and 5Ј-TCGACATCGGGGCGGGGCATCCGCTG-CA-3Ј. The Sp1 binding site is underlined. The modified pBKCMV vector and the modified pBKCMV vector containing rat ZBP-89 cDNA (pBKCMV-ZBP-89) have been described previously (20) . To each 60-mm dish, 0.1 g of ␥F-gal, 5 g of pOD150WTLuc, and 0.1-0.75 g of expression vectors were added. The control vectors pPacO and modified pBKCMV were used to keep the total amount of DNA constant. The medium was not changed before or after the addition of DNA complexes, and the cells were harvested 48 h later. The cells were washed two times with phosphate-buffered saline and lysed in Reporter Lysis Buffer (Promega, Madison, WI). Generally, 5 l of cell lysate were used in the Galacto-Light™ ␤-galactosidase assay (Tropix, Inc., Bedford, MA) and 50 l of lysate were used to determine the luciferase or chloramphenicol acetyltransferase activity (30, 31) . The luciferase or chloramphenicol acetyltransferase activity was normalized to ␤-galactosidase activity, and each transfection was done in triplicate. Nuclear extract was harvested, as described above, from SL2 cells transfected with 16 g of pBKCMV-ZBP-89 and 11 g of pPacSp1 per 150-mm dish. EMSAs were performed with SL2 nuclear extract using the same protocol as described for Jurkat nuclear extract.
RESULTS
Characterization of DNA Binding by NF-ODC 1 -We have used EMSAs as a tool to further characterize and identify the protein responsible for the DNA binding activity we called NF-ODC 1 . Fig. 1 shows the sequence of the Ϫ123 to Ϫ91 GC box in the proximal promoter in the ODC gene that contains both the Sp1 and NF-ODC 1 binding sites and also the sequences of four double-stranded oligonucleotides that we used as probes and competitors in several of the EMSAs detailed in this study. GC WT contained the sequence of the wild type GC box. In GC WT6 , the wild type sequence was altered so that Sp1 binding to the oligonucleotide was greatly reduced, but NF-ODC 1 Jurkat nuclear extracts, a complex band shift pattern resulted ( Fig. 2A, lane 2) . We previously showed that the first complex (C1) was due to Sp1 binding and the third complex (C3) was the result of NF-ODC 1 binding (19) . There were two other specific DNA-protein complexes, C2 and C4, in which the identity of the protein component was unknown. When radiolabeled GC S was used as probe, Sp1, C2, and C4 complexes were detected, but there was no NF-ODC 1 complex ( Fig. 2A , compare lanes 2 and 7). When GC S was used as an unlabeled competitor, no Sp1, C2, or C4 complexes were seen, indicating that GC S had high affinity for Sp1 and the proteins in C2 and C4 ( Fig. 2A, 
FIG. 2.
The GC box sequence binds several proteins in Jurkat nuclear extract. A, EMSA was performed, as detailed under "Materials and Methods," using Jurkat nuclear extract (10 g of total protein/ lane). The oligonucleotides used as probes are indicated, as is the molar -fold excess of unlabeled competitors (WT refers to GC WT , N refers to GC N , and S refers to GC S ). The reaction in lanes 1 and 6 contained free probe only, with no protein. The four shifted bands of interest are indicated. All the reactions were run on the same gels; only film exposure times differ; lanes 1-5 were exposed for 4 h, and lanes 6 -10 were exposed for 12 h. B, EMSA was performed using Jurkat nuclear extract (10 g of total protein/lane) with GC N as probe. A 100-fold molar excess of unlabeled GC S was added to the reactions to eliminate the radioactive bands of C1, C2, and C4. Fig. 3A, lane 2) .
The DNA binding domains of many proteins that bind to GC-rich regions contain zinc finger motifs. To determine if the interaction between NF-ODC 1 and DNA required zinc, EMSAs were performed with the zinc chelator, o-phenanthroline. To eliminate the radioactive bands of C1, C2, and C4, unlabeled GC S was added to each binding reaction. Increasing the amount of zinc chelator resulted in decreasing amounts of the NF-ODC 1 complex (Fig. 2B) . When zinc was added back to the reaction, in the form of Zn 2 SO 4 , NF-ODC 1 binding was restored. These results indicate that NF-ODC 1 binding is dependent on the presence of zinc.
To determine if the complexes formed with the GC-box contained known members of the Sp1 family of transcription factors, specific antibodies were employed (Fig. 3) . Antibodies to Sp1, Sp2, Sp3, and Sp4 were added separately to binding reactions containing GC N as probe and Jurkat nuclear extract (Fig. 3A) . As expected, NF-ODC 1 binds strongly to this probe, while Sp1 gives a weak signal. GC S was used as an unlabeled competitor to eliminate Sp1 binding and to identify the NF-ODC 1 complex (Fig. 3A, lane 3) . Binding of NF-ODC 1 was not inhibited by any of these antibodies (Fig. 3A, compare lane 2  with lanes 4 -7) . The Sp1 band was supershifted as expected when the Sp1 antibody was used (Fig. 3A, lane 7) . To determine if C2 or C4 contained proteins that were related to Sp1, visualization of these two proteins was enhanced two ways. GC WT6 (see Fig. 1 ), which binds NF-ODC 1 , but none of the other proteins, was used as a competitor, eliminating the NF-ODC 1 complex (Fig. 3B, compare lanes 2 and 3) . Additionally, antiSp1 was added to the reaction so that the Sp1 complex was shifted to a higher location on the gel (Fig. 3B, compare lanes 3  and 4) . Not only were C2 and C4 better visualized, but an additional complex was detected, C1b, which was normally hidden by the Sp1 complex. When anti-Sp4 was added to the binding reaction, C1b diminished in intensity but a residual complex remained (Fig. 3B, compare lanes 4 and 5) . Doubling the amount of anti-Sp4 did not further reduce the residual band (Fig. 3B, lane 6) . Pre-incubation of the control peptide, P4, with the Sp4 antibody eliminated the influence of the antibody on the intensity of C1b (Fig. 3B, compare lanes 5 and 7) . When Sp3 antibodies were added to the reaction mixture, C2 and C4 greatly diminished in intensity (Fig. 3B, compare lanes 4 and  8) . The control peptide, P3, eliminated the effect (Fig. 3B,  compare lanes 4, 8, and 9) . Anti-Sp2 caused no change in the banding pattern (data not shown). These results indicate that C2 and C4 are both due to binding of Sp3. In addition, Sp4 appears to be involved in a portion of the C1b complex.
GC factor (GCF; Ref. 32), MYC-associated zinc finger protein (MAZ; Ref. 33) , and specific members of the Egr-1 family (34 -36) are DNA-binding proteins that are expressed in many different cell types, contain zinc finger domains, act as transcriptional repressors, and specifically bind DNA sequences very similar to the NF-ODC 1 binding sequence (Fig. 4A) . When double-stranded oligonucleotides containing the GCF or Egr-1 binding sites were used in EMSAs as unlabeled competitors, they did not compete for NF-ODC 1 binding (Fig. 4B) . Since DNA binding activity of both MAZ and NF-ODC 1 have been previously characterized in HeLa nuclear extract (19, 33) , supershift experiments with antibodies to MAZ were performed using this type of extract (Fig. 4C) . Unlabeled GC S was added to reaction in lanes 2-5 to identify the NF-ODC 1 complex. When anti-MAZ was added to the binding reactions containing GC WT as probe, no reduction in NF-ODC 1 binding was seen (Fig. 4C, compare lane 2 to lanes 4 and 5) . The same experiment was done using Jurkat nuclear extract with the same results; there was no reduction in NF-ODC 1 binding with the addition of anti-MAZ (data not shown). As a positive control for the effectiveness of the MAZ antibody, in vitro translated MAZ was used in supershift experiments (Fig. 4C ). There was a significant amount of binding activity in the in vitro transcription/translation reaction mixture without any MAZ expression vector added (Fig. 4C, compare lanes 6 and 12) . When the MAZ expression vector was added to the in vitro transcription/translation reaction, an additional complex was seen (Fig. 4C , compare lanes 7 and 12). Competition with unlabeled oligonucleotides determined that this complex was specific. When oligonucleotide GC N was added as an unlabeled competitor, the intensity of the MAZ band was diminished significantly (Fig.  4C, compare lanes 7 and 8) ; the Sp1 binding site (oligonucleotide GC S ) competed to a small degree for MAZ binding as 
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previously reported (37) (Fig. 4C, compare lanes 7 and 9) and oligonucleotide E which had no sequence similarity to the MAZ binding site, did not compete for MAZ binding (Fig. 4C , compare lanes 7 and 10). MAZ antibody supershifted the specific band formed by in vitro synthesized MAZ (Fig. 4C, lanes 7 and  11) . Taken together, these results indicate that neither GCF, MAZ, nor Egr-1-like proteins are responsible for the NF-ODC 1 binding activity.
Identification of a cDNA Encoding NF-ODC 1 Binding Activity-We used a yeast one-hybrid selection method (see "Materials and Methods") to isolate a cDNA encoding the protein responsible for the NF-ODC 1 binding activity. We screened a human leukemia cDNA library using three tandem copies of the GC N sequence as the target binding sequence. After screening approximately 1 ϫ 10 6 independent clones, five independent positive clones were identified, four of which were partially sequenced. One had 88% identity with the mouse interleukin 2 receptor, and the other three had 50 -60% identity with known zinc finger DNA-binding proteins over the regions sequenced, but appeared to be cDNAs that coded for as yet unidentified proteins. The further characterization of these four clones is presently under way. The fifth clone, NF6, was sequenced in its entirety and was found to have 98% identity with a cDNA that encodes a human CACCC element-binding protein called ht␤ NF6 was not a full-length clone; it started 100 nucleotides downstream of the translational start site of the ht␤/rat ZBP-89/BFCOL1 cDNAs. The "Gene Trapper" method (see "Materials and Methods") was used to identify other hZBP-89 clones from a normal human leukocyte library in order to obtain the complete cDNA sequence. The full-length NF-ODC 1 cDNA (accession no. AF039019) contains 2798 nucleotides and is the human homologue of rat ZBP-89/mouse BFCOL1. The sequence of human ZBP-89 is 92% and 96% identical at the nucleotide and amino acid levels, respectively, with both the mouse and rat sequences. In comparison to the sequence of ht␤, the NF-ODC 1 sequence is 98% identical at the nucleotide level, and the amino acid sequence is 98% identical to ht␤ in the regions in which the reading frames are the same (see "Discussion"). The NF-ODC 1 cDNA sequence has the same translational start site as the three other cDNAs and the same termination site as both ZBP-89 and BFCOL1.
Human ZBP-89 Is the Protein Responsible for the NF-ODC 1 DNA Binding Activity-Several approaches were taken to establish that human ZBP-89 is indeed the protein responsible for the NF-ODC 1 binding activity. We developed a four-step purification procedure that used Jurkat nuclear extract as starting material. The steps included an ammonium sulfate precipitation, desalting, fractionation on a Mono Q column, and adsorption to a DNA affinity column made with the GC N double-stranded oligonucleotide (see "Materials and Methods" for details). We used EMSAs to determine the protein fractions that contained NF-ODC 1 binding activity and to compare the amount of NF-ODC 1 binding activity between the different protein fractions. The first three steps did not result in significant overall enrichment of activity, but they did combine to remove the majority of Sp1 and Sp4 proteins. There was substantial enrichment (34-fold) in NF-ODC 1 binding activity in the protein fraction eluted from the DNA affinity column compared with the starting material (data not shown). If human ZBP-89 were responsible for this binding activity, this protein should follow NF-ODC 1 binding activity during the enrichment procedure. Equal amounts of total protein from three steps of the purification procedure were analyzed by immunoblot analysis using a polyclonal antibody to rat ZBP-89 (Fig. 5) . In vitro WT (0.1 pmol) and Jurkat nuclear extract (10 g of total protein). GCF and Egr-1 are double-stranded oligonucleotides containing the DNA binding site for GCF and the Egr-1 family, respectively (see "Materials and Methods" for oligonucleotide sequences). These unlabeled double-stranded oligonucleotides were added to the indicated binding reactions at the indicated molar -fold excess at the same time as the GC WT probe but before the nuclear extract. All reactions were run on the same gel and exposed to film for same length of time. C, a supershift experiment was performed as detailed under "Materials and Methods." The anti-MAZ was incubated with the protein solution for 1 h before the DNA (probe plus unlabeled competitors) was added to the binding reaction. Radiolabeled GC WT (0.1 pmol/reaction) was the probe in all of the binding reactions, which contained either HeLa cell nuclear extract or the product of a MAZ in vitro transcription/translation reaction. Binding reactions in lanes 1-5 contained 5 g of total protein/lane of HeLa cell nuclear extract; lane 6 contained no protein; lanes 7-11 contained equal amounts of an in vitro transcription/translation reaction using pMAZHH (a MAZ expression vector); and lane 12 contained the same amount of a control in vitro transcription/translation reaction without vector. To identify the NF-ODC 1 complex, unlabeled GC S was added at 75-fold molar excess to reactions in lanes 2-5. Unlabeled competitors as indicated were added to the reactions at the same time as the probe. N refers to GC N , S refers to GC S , and E refers to a double-stranded oligonucleotide that contained the E-box binding site for c-Myc. SS indicates the location of the supershifted complex. The location of the complexes containing NF-ODC 1 and MAZ are indicated. All lanes are from the same gel; only film exposure times differ. Lanes 1-5 were exposed for 6 h, and lanes 6 -12 were exposed for 2 days. translated rat ZBP-89 was analyzed at the same time as a positive control. Rat ZBP-89 ran as a doublet just above the 103-kDa marker (Fig. 5, lane 1) , as did the human ZBP-89 in protein fractions from the purification procedure (Fig. 5, lanes  3-5) . This was a higher molecular weight than earlier reported, but was a consistent result using this 7.5% acrylamide mini-gel format and the Bio-Rad prestained markers. There was a 37-fold enrichment of the ZBP-89 signal by densitometry between the DNA affinity fraction and the Jurkat nuclear extract. This enrichment in human ZBP-89 paralleled the 34-fold enrichment of NF-ODC 1 binding activity in these protein fractions.
The ability of antibodies against ZBP-89 to inhibit NF-ODC 1 binding activity was tested. Jurkat nuclear extract was incubated with both anti-Sp1 and anti-Sp3 to both act as a control to show the specificity of the ZBP-89 antibody and to enhance the visualization of the NF-ODC 1 complex (Fig. 6, compare  lanes 1 and 2) . As shown in Fig. 3 , neither of these antibodies inhibited the NF-ODC 1 binding. When anti-ZBP-89 was added with or without the addition of anti-Sp1 and anti-Sp3, the NF-ODC 1 binding to oligonucleotide GC N was abolished (Fig. 6,  lanes 3 and 4) . We used competition with a truncated form of rat ZBP-89 to show that this inhibition of NF-ODC 1 binding was due to a specific interaction with ZBP-89 antibody (Fig. 6) . The expression vector, B22, contained a COOH-terminal truncated rat ZBP-89 cDNA. The B22 cDNA encoded a 64-kDa protein that contained the four zinc finger domains and was able to bind to the NF-ODC 1 binding site. To detect the competition between B22 and NF-ODC 1 for anti-ZBP-89, the antibody could not be in excess. Therefore, one third of the amount of anti-ZBP-89 was used in lanes 8 and 10 as compared with lanes 3 and 4 in Fig. 6 . This low level of antibody still strongly inhibited the NF-ODC 1 binding activity (Fig. 6, compare lanes  5 and 8) . When in vitro translated B22 was added instead of the control translation reaction, NF-ODC 1 binding activity was partially restored (Fig. 6, compare lanes 5, 8, and 10 ) and the B22 binding was greatly reduced (Fig. 6, compare lanes 6 and  10) , consistent with competition for the same antibody binding site.
A series of double-stranded oligonucleotides was used as competitors in EMSAs to compare the binding specificity of NF-ODC 1 and ZBP-89. The sequence changes in these oligonucleotides were placed into the GC N context (Fig. 7B ). Fig. 7A shows an EMSA where GC N was radiolabeled and three different oligonucleotides were used as competitors. The ability of the three different double-stranded oligonucleotides to compete for either NF-ODC 1 binding or human ZBP-89 binding was compared. The degree of competition by the three oligonucleotides was indistinguishable between Jurkat nuclear extract and human ZBP-89. GC N competed the best, whereas GC N4 did not compete at all. Fig. 7B summarizes the results of EMSAs in which these oligonucleotides and nine additional doublestranded oligonucleotides were used as unlabeled competitors. For each individual oligonucleotide, the relative intensity of the NF-ODC 1 signal did not differ significantly from that of the human ZBP-89 signal, indicating that there was no significant difference in the affinity of each individual oligonucleotide to NF-ODC 1 compared with human ZBP-89.
The binding affinities of both NF-ODC 1 and ZBP-89 differed between the twelve oligonucleotides. When GC N , GC N7 , GC N3 , or GC N12 were used as competitors, the signal was decreased by varying degrees. GC N , the wild type sequence, decreased the signal intensity to the largest extent indicating that ZBP-89/ NF-ODC 1 had lower affinity for GC N7 , GC N3 , and GC N12 compared with the wild type binding site. In contrast, there was no In lanes 1-6, 8 , and 10, binding reactions containing 2.5 g of Jurkat nuclear extract were pre-incubated with or without the indicated antibody for 1 h before the addition of radiolabeled GC N (0.1 pmol/reaction). Reactions in lanes 3 and 4 contained 3 l of anti-ZBP-89, and reactions in lanes 2 and 3 contained 2 l of both anti-Sp1 and anti-Sp3. In lanes 8 and 10, 1 l of anti-ZBP-89 was incubated overnight with 7 l of either B22 in vitro translation reaction or control in vitro translation reaction prior to the incubation with the Jurkat nuclear extract. In contrast, in lanes 5 and 6, 7 l of either B22 in vitro translation reaction or control in vitro translation reaction was incubated overnight without anti-ZBP-89 prior to the incubation with the Jurkat nuclear extract. In lanes 7 and 9, reactions contained probe and 7 l of either the control or B22 in vitro translation reaction, respectively; no Jurkat nuclear extract was added. Unlabeled GC S was added at 75-fold molar excess to the reactions in lanes 5-10 to eliminate complexes containing the Sp1 family. SS indicates the supershift complexes. Locations of NF-ODC 1 , Sp1, Sp3, and B22 complexes are indicated. change in the signal intensities when GC N2 , GC N4 , GC N8 , GC N9 , GC N10 , GC N11 , GC N13 , or GC N14 were used as competitors compared with when no competitor was used, suggesting that the five cytidines that were individually altered in these competitors sequences were essential for the binding of ZBP-89/NF-ODC 1 to the DNA. These results were based upon EMSAs in which a 15-fold molar excess of oligonucleotides were used to compete radiolabeled GC N . The same result was observed when the competitors were used at a 5-fold molar excess (data not shown). These results, all taken together, strongly suggest that human ZBP-89 is the protein responsible for the NF-ODC 1 binding activity.
ZBP-89 Represses Activation of the ODC Promoter by Sp1-Transient transfections in SL2 cells were used to determine the effect of ZBP-89 expression on ODC promoter activity. EMSAs, with radiolabeled GC N , were performed using nuclear extract isolated from SL2 cells transfected with Sp1 and ZBP-89 expression vectors. Results indicated that both proteins were synthesized and capable of binding DNA (data not shown). SL2 cells were transfected with 5 g of a luciferase reporter construct containing Ϫ133 to ϩ16 of the ODC promoter (pOD150WTLuc) and increasing amounts of a Sp1 expression vector (0.2, 0.5, or 0.75 g). In addition, either 0.5 g of a ZBP-89 expression vector or 0.5 g of the empty expression vector were added to each transfection. Without the addition of ZBP-89 expression vector, the ODC promoter construct was activated by Sp1 (Fig. 8A) . ZBP-89 expression repressed the Sp1 activation of the ODC promoter at all three levels of Sp1 expression (Fig. 8A) . This repression was also seen with 0.2 g of ZBP-89 expression vector, but to a lesser degree (data not shown). To determine that the ZBP-89 repression was specific for promoters containing its binding site, the ODC promoter construct, pOD150M12Luc was created. This construct contained a 20-base pair deletion, which resulted in the removal of 6 out of 11 of the base pairs in the ZBP-89 binding site but leaving the Sp1 binding site intact. EMSAs showed that the ODC promoter region in pOD150M12Luc did not bind ZBP-89, but still bound Sp1 (data not shown). In SL2 cells, pOD150M12Luc was activated by Sp1, but instead of repressing this activation, ZBP-89 expression slightly enhanced the N , and the indicated oligonucleotides as unlabeled competitors at the indicated molar -fold excess (see "Materials and Methods" for details). B, listed are the names and corresponding sequences of the double-stranded oligonucleotides used as competitors in EMSAs as described in A. Phosphorimage analysis was used to determine the signal intensity of the NF-ODC 1 complex or the ZBP-89 complex with or without a competitor added to the reaction. The relative signal intensity in the presence of each competitor was then determined by setting the intensity of the signal without competitor at 1.00. The unlabeled competitors were at 15-fold molar excess.
FIG. 8. ZBP-89 inhibits activation of the ODC promoter by Sp1.
Transient transfections were performed with SL2 cells as detailed under "Materials and Methods." Increasing amounts of pPacSp1 expression vector were added to 5 g of the ODC construct, pOD150WTLuc (A) or pOD150M12 (B) with 0.5 g of the modified pBKCMV-ZBP-89 expression vector (open bars) or 0.5 g of the empty modified pBKCMV vector (black bars). pPac0 vector was added as needed to keep total amount of DNA per transfection constant. Each transfection was done in triplicate. Luciferase activity was normalized to ␤-galactosidase activity, and the standard deviation from the mean is presented. Shown in this figure is one of at least three independent experiments performed. The normalized luciferase values differed between experiments, but the trend was the same.
Sp1 effect at both 0.5 g (Fig. 8B) or 0.2 g (data not shown) of ZBP-89 expression vector. The maximum activation by Sp1 of pOD150M12Luc was generally larger than the maximum activation of pOD150WTLuc, as shown in the experiment depicted in Fig. 8 . Sp1 may have higher affinity for pOD150M12Luc than the wild type ODC promoter, but further studies are needed to confirm this hypothesis. A second control plasmid, BCAT-S, was made which contained the ODC Sp1 binding site and the E1b TATA box fused upstream of the chloramphenicol acetyltransferase gene. This construct was also activated by Sp1 expression, but not inhibited by ZBP-89 (data not shown).
DISCUSSION
The synthesis and degradation of ODC is highly regulated, and transcriptional regulation is a major route through which the levels of ODC are controlled. The proximal promoter region of the ODC gene contains a GC box that we have shown previously to be involved in both basal and induced transcription. This GC-rich region contains at least three overlapping protein binding sites. Two are sites for known transcription factors, Sp1 and WT1, which we and others have shown to bind in this region and which may participate in regulating transcription of the ODC gene (19, 31, 40, 41) . 2 Previous results from the use of in vitro binding assays and in vivo promoter studies have suggested the existence of a third protein, NF-ODC 1 , that also binds in this region and appears to repress transcription of the ODC gene (19) . The DNA sequence of the NF-ODC 1 binding site in the ODC promoter was used in a yeast one-hybrid screen to identify the human protein responsible for this binding activity. One of the five positive clones obtained had 98% and 92% identity to the cDNAs encoding human ht␤ and rat ZBP-89, respectively (20, 38) . The full-length cDNA sequence was 92% identical to the rat ZBP-89, indicating that we had cloned the human homologue of rat ZBP-89.
Several different approaches were used to establish that human ZBP-89 is indeed the protein responsible for the NF-ODC 1 binding activity. Using in vitro binding as an activity assay, we partially purified the NF-ODC 1 activity with the final step being adsorption to a DNA affinity column. Enrichment of the NF-ODC 1 binding activity paralleled the enrichment of immunoreactive ZBP-89 protein during this procedure. NF-ODC 1 proved remarkably difficult to purify, because of its extreme lability. During our initial characterization of NF-ODC 1 binding activity, we found that if protease inhibitors were not used during the preparation of nuclear extract, there were two additional protein complexes with faster mobility associated with the NF-ODC 1 binding activity (19) . Immunoblot analysis, using antibody to ZBP-89, indicated that NF-ODC 1 began to break down dramatically after fractionation on the DNA affinity column even though a complex mixture of protease inhibitors was used throughout the purification procedure (data not shown). A second line of evidence, demonstrating that NF-ODC 1 and human ZBP-89 were the same protein, came from the influence of anti-ZBP-89 on NF-ODC 1 binding. In binding studies with Jurkat nuclear extract, NF-ODC 1 binding was abolished by addition of anti-ZBP-89. EMSAs also showed that the NF-ODC 1 from Jurkat nuclear extract and human ZBP-89 from in vitro translation resulted in protein-DNA complexes that migrated to the same location on the gel (data not shown). More importantly, when the binding affinities of 12 different double-stranded oligonucleotides were studied, each individual oligonucleotide had indistinguishable affinities for the two proteins. These three different lines of evidence indicate that ZBP-89 is the protein responsible for the NF-ODC 1 binding activity that we have previously characterized. These studies do not however, eliminate the possibility that other related proteins may bind the NF-ODC 1 site and function in the transcriptional regulation of the ODC gene.
ZBP-89 protein has now been identified, including isolation of cDNAs encoding the protein, in four different promoter systems and three species: rat ZBP-89, gastrin gene (20) ; mouse BFCOL1, type I collagen genes (39); human ht␤, T-cell receptor genes (38) ; and human NF-ODC 1 , ODC gene (current study). Two deletions of single base pairs in the ht␤ sequence compared with the ZBP-89/BFCOL1/NF-ODC 1 sequence result in an in-frame stop codon at nucleotide 1753 in the ht␤ cDNA, resulting in a polypeptide with a predicted mass of 49 kDa. In contrast, the first in-frame stop codon in the ZBP-89/BFCOL1/ NF-ODC 1 sequence occurs 1018 nucleotides downstream, resulting in a polypeptide with the predicted mass of 89 kDa (for details, see Ref. 20) . Analysis by Southern blot indicates only one gene (20, 38) . Therefore, ht␤ appears to be a truncated version of ZBP-89/BFCOL1/NF-ODC 1 . The mechanism that produces the differences between ZBP-89 and ht␤ is not known, but alternative splicing would not appear to explain the singlebase deletions. A major band at around 49 kDa, which would represent the ht␤ protein, has not been detected in any of the immunochemical studies of ZBP-89. There are several potential translational start sites in all of the cDNAs, and doublets have been seen upon gel electrophoresis of both the in vitro and in vivo translated ZBP-89/BFCOL1/NF-ODC 1 (current study and Refs. 20 and 39). Amino acid sequence analysis indicates that this protein has several distinct motifs including four C2H2 Krü ppel-type zinc finger motifs (making up the DNA binding domain), one acidic and two basic regions and, in all but ht␤, a serine-rich region in the carboxyl terminus. The sequence homology to known proteins and the corresponding deduced functions of these motifs have been discussed previously (20, 38, 39) .
Our previous studies determined that the NF-ODC 1 binding site in the ODC promoter is GCCCCTCCCCC. Methylation of any of the guanine residues on either strand of DNA interfered with NF-ODC 1 binding to some degree, and nuclease protection experiments showed that the 5Ј half of the NF-ODC 1 binding site overlaps with the 3Ј half of the Sp1 site in the ODC promoter (19) . The additional binding studies reported here showed that 5 C/G pairs out of the 11 base pairs in the NF-ODC 1 binding site were required for binding of ZBP-89, and a significant decrease in the affinity for ZBP-89 was seen when four additional nucleotides were individually mutated. These results suggest a consensus binding site for ZBP-89: gccCCtxCxCC, where the uppercase C represent the five essential cytidines, the lowercase letters represent residues that are involved in binding but not essential, and x represents residues that have not been mutated (Fig. 9) . All of the ZBP-89 binding sites on the genes encoding the type I collagens (Ϫ180, Proa2(I); Ϫ168, Pro-a1(I); and Ϫ194, Pro-a1(I)), and the T-cell receptor (TCR V␤8.1, TCR ␣ silencer I), contain these five essential cytidine residues (Fig. 9) . The binding site on the gastrin promoter contains four out of the five essential cytidine residues. Importantly, the results of other binding studies with various mutations within these sites are consistent with the importance of these residues (20, 39) . There must be additional requirements beyond the five essential cytidines since several other characterized binding sites contain this motif, but do not in most cases compete for ZBP-89 binding (compare, for example, the binding sites for Egr-1, MAZ, GCF, and Sp1; Figs. 1 and  4) . Interestingly, except for the gastrin and the Ϫ194, Pro-␣1(I) sites, all of the ZBP-89 binding sites contain in addition to the five essential cytidines, five consecutive cytidine residues pre-ceded by either a T or an A (see Fig. 9 ). Both the gastrin and Ϫ194, Pro-␣1(I) sites appear to have significantly lower affinity for ZBP-89. In EMSAs using either in vivo or in vitro translated humans ZBP-89, there was no competition by the gastrin binding site at either 5-or 15-fold molar excess with the ODC binding site (data not shown). Hasegawa and co-workers (39) showed that the Ϫ194, Pro-␣1(I) site had a much less affinity than either the Ϫ168, Pro-␣1(I) or the Ϫ180, Pro-␣2(I) site for BFCOL1. Consistent with these observations, the Sp1 binding site competes significantly with the gastrin site for ZBP-89 binding, but does not compete with either the ODC or Ϫ180, Pro-␣2(I) site for ZBP-89 binding (current study and Refs. 20 and 39). Relative to the ODC gene, the ZBP-89 binding site in the TCR V␤8.1, the TCR ␣ silencer I, the Ϫ194, Pro-␣1(I), and the gastrin promoters are inverted. The importance of the orientation of the ZBP-89 binding site relative to the transcriptional start site is not known.
ZBP-89 is an ubiquitous protein found in most cell types and tissues examined to date (19, 20, 23, 38, 39) and has been shown to be overexpressed in gastric cancer (23) . The function of ZBP-89 in transcriptional regulation is currently under investigation. A general scheme has emerged; ZBP-89 binds to a GC-rich region that is within the first 200 base pairs downstream of the transcriptional start site of the gene. The ZBP-89 binding site is overlapping or adjacent to other known transcription factors, in particular, Sp1. Mutations in the ZBP-89 binding site result in significant changes in the promoter activity. In earlier studies, we showed that the activity of the ODC promoter increased in several cell lines when the NF-ODC 1 site was mutated (19) . In GH 4 cells, a cell line derived from a rat pituitary tumor, ZBP-89 represses both basal and EGF-stimulated promoter activity of the gastrin gene, with no effect on expression of a control promoter construct (20) . When the BFCOL1 site was mutated in the promoter of the type 1 collagen genes, the promoter activity increased 3-4-fold in transient transfection experiments (43, 44) . However, Hasegawa and co-workers (39) did not detect an effect of BFCOL1 on the pro-␣2(I) collagen promoter in transient co-transfection experiments in BALB/c 3T3 fibroblasts or S194 B cells. They did show that a fusion polypeptide between the COOH terminus of BFCOL1 and the yeast Gal4 DNA-binding domain activated a reporter construct, suggesting that the COOH terminus contains a domain with transactivating potential in yeast. Wang and co-workers (38) showed that ht␤ slightly activated the T-cell receptor gene and inhibited the silencing effect of the mouse T-cell receptor ␣ gene silencer in HeLa cells. The endogenous level of ZBP-89 and other relevant transcription factors such as Sp1 may be too high in the BALB/c 3T3, S194 B, or HeLa cells to see a significant effect of additional ZBP-89. In this study, we used SL2 cells for in vivo promoter analysis. This insect cell line has an advantage over mammalian cell lines in that there are no detectable levels of the Sp1-like activity (27) or NF-ODC 1 activity (data not shown). Transient expression of Sp1 in SL2 cells increased the ODC promoter activity in a dose-dependent manner with the maximum increase depending on the region of ODC promoter used (40) . 3 All three of the constructs used in this study contained a Sp1 binding site and were stimulated by Sp1 expression. ZBP-89 expression repressed the Sp1 activation only of the ODC wild type promoter construct, which contained the ZBP-89 binding site. This repression was not seen with the constructs that did not contained the ZBP-89 binding site, BCAT-S or pOD150M12Luc.
The limited functional studies done to date suggest that ZBP-89 has the potential to either repress or stimulate transcriptional activity, depending on the particular promoter. This duality is seen with other transcription factors, and there are several paradigms that explain this phenomenon, including competition with different transcriptional factors for DNA binding, interference with the activity of DNA-bound activators, alternative splicing, alternative translational initiation, and positional effects of binding sites (42, 45, 46) . As mentioned earlier, all of the known ZBP-89 binding sites either overlap or are in close proximity to binding sites of other transacting proteins. These include binding sites for Sp1, Sp3, Sp4, and WT1 on the ODC gene (current study, Ref. 41 , and Footnote 2), for Sp1 and Krox on the pro-␣2(I) gene (39) , and for Sp1 on the gastrin gene (20) . ZBP-89 may repress transcription by competing with these other factors for DNA binding, thereby decreasing the activation. Studies have shown, for both the gastrin and ODC promoters, that the Sp1 and ZBP-89 binding sites overlap and that these two factors bind in a mutually exclusive manner (19, 20) . However, more detailed studies must be undertaken to differentiate between this mechanism and at least two other possibilities: ZBP-89 may act as an active repressor by directly inhibiting transcriptional initiation, or ZBP-89 may mask or quench the activity of other factors through protein-protein interactions. FIG. 9 . The suggested consensus sequence for the ZBP-89 binding site is shown. Bold and underlined letters represent nucleotides that were required for ZBP-89 interaction with its binding site in the ODC gene. The lowercase letters in the consensus site represent nucleotides that when altered lowered the affinity to ZBP-89 but did not abolish binding, and x represents residues that were not tested. The known ZBP-89 binding sites in the promoters of the ODC gene, the type I collagen genes (Pro-␣2(I); Ϫ168, Pro-␣1(I); and Ϫ194, Pro-␣1(I)), the T-cell receptor genes (TCR V␤8.1, TCR ␣ silencer I), and the gastrin gene are aligned with the consensus sequence. The asterisk denotes sequences that are inverted in relationship to the transcriptional start site when compared with the binding site in the ODC promoter.
